EATONTOWN N.J. - Mar. 30, 2020 Immunostics Inc is announcing the release of AFIAS COVID-19 Ab test in conjunction with their AFIAS-1 and AFIAS-6 analyzer platforms. This test is intended for use by laboratories certified to perform high complexity testing, and at the point-of-care when covered by the laboratories CLIA certificate for high-complexity testing.
Immunostics’ AFIAS COVID-19 test is truly innovative because it can be performed on serum, plasma, venous whole blood or fingerstick capillary whole blood sample to qualitatively detect the presence of IgM and IgG antibodies to the novel coronavirus SARS-CoV-2 in just 10 minutes.
Immunostics’ AFIAS-1 and AFIAS-6 analyzer platform are small and portable instruments that can be deployed anywhere to enable rapid COVID-19 antibody testing wherever needed.
AFIAS COVID-19 Ab test does not require swabs and other related materials making testing simple and easy.
Immunostics AFIAS COVID-19 tests are available now and will have the capacity to deliver 20,000 tests per day. Immunostics expects to be able to ramp up our manufacturing abilities to deliver 40,000 tests per day by May 2020
AFIAS COVID-19 platform are able to deliver up to 36 results per hour ( e.g. 6 tests per hour for AFIAS-1; 36 tests per hour for AFIAS-6)
AFIAS comes with full connectivity (LAN, USB, RS232) and can store 5,000 patient results
According to Dr. Gianrico Farrugia, CEO Mayo Clinic, "the serology antibody test is very important to understand who has an antibody and therefore can be presumed to have had contact with the virus and has mounted a response to it."
Please contact adamchoe@immunostics.com for more info.